FLA‐IDA salvage chemotherapy combined with a seven‐day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia
Authors:
Open Access
- 4 November 2019
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 188 (3) , e11-e15
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (HE 5240/5‐2, HE 5240/6‐1, HE 5240/6‐2)
- Horizon 2020 (No. 638035)
This publication has 11 references indexed in Scilit:
- Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaNature Medicine, 2018
- Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AMLBlood, 2018
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaHaematologica, 2018
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology, 2017
- Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cellsSignal Transduction and Targeted Therapy, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failureLeukemia, 2017
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous LeukemiaCancer Discovery, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Mitochondria—Judges and Executioners of Cell Death SentencesMolecular Cell, 2016